Sign up
Pharma Capital
EPIC: VPT
Market: TSX-V
52-week High/Low: C$0.51 / C$0.17
Sector: Health Care, Equipment & Services
Market Cap: C$17.52M

VentriPoint is a public company (TSXV: VPT) dedicated to making heart analysis convenient and easy. By using knowledge-based techniques, our VMS software is able to reconstruct the right ventricle and give volume information that is equivalent to an MRI.

VentriPoint Diagnostics

www.ventripoint.com

Interactive graph

col 3
col 4
col 5
col 6

Big picture - Why invest in VentriPoint Diagnostics

VentriPoint Diagnostics Snapshot

VentriPoint has created a diagnostic ultrasound tool to monitor patients with heart disease, a leading cause of death in developed countries. VMS(TM) is the first cost-effective and accurate diagnostic tool for measuring right ventricle heart function. Congenital heart disease in children is the first application in a suite of applications for all major heart diseases including pulmonary hypertension, cardiovascular disease and heart failure - a multi-billion dollar market potential. Canada and Europe (CE Mark) have granted approval for the sale of its VMS(TM) diagnostic tool and is pursuing the US-FDA approval through the 510(k) process.

Please click here to view Ventripoint's video demo

 

Imaging the Right Ventricle


We have designed a new heart visualization system that will save you time and money. Our system is used to evaluate right heart function and does so as accurately as the current gold standard, MRI, and in a fraction of the time, resulting in better efficiency and cost savings for your hospital.


Our system was initially designed for congenital heart disease and we have approval to sale for Tetrology of Fallot and Systemic Right Hearts (d-TGAs) in both Canada and Europe. We are currently awaiting FDA approval and actively pursuing new applications such as Pulmonary Arterial Hypertension.


Angelo (VMS™), our heart visualization system, is after Michelangelo who taught his students to put dots on a page to get the proportionality correct before starting to draw an image.


Our technology uses knowledge-based reconstruction (KBR), which essentially is a library of disease specific hearts. Ultrasound images are acquired using standard clinical views (ie. Parasternal, apical, etc). After acquisition, the physician or sonographer identifies anatomical landmarks (values annulus, RV endocardium, RV Septum, etc) with dots on a number of the 2D ultrasound views through the heart. We also have a sensor (GPS) on the ultrasound probe so we know where the 2D slice (plane) is in 3D space. In this way the precise anatomical landmark is located in 3D space. Our research has proven that a constellation of 25 of these points is all that is required to define the ventricle of the heart and to allow an accurate 3D image to be constructed using KBR.


We have built a library of hearts of normal shapes and sizes as well as hearts with the particular abnormalities characteristic of the heart disease of interest. This library then becomes the catalog of possible shapes and sizes the heart can possibly be. Through a complicated regional statistical process the heart-best-shape for the 25-point constellation is selected. The resultant heart image is used to calculate heart volumes (End Diastolic/End Systolic), ejection fraction, and cardiac output. Independent research by leading cardiologists around the world has shown these calculated numbers are as accurate as MRI, CT or 3D-echo or any other way of measuring the heart. See Journals here


Our system requires about 5 minutes of acquisition time, post standard imaging protocol, and about 10-15 minutes of Dot placements. Since the Dot placements are in your control, we have created tools to help ensure you have accurate reconstructions.


Angelo’s Advantages

  • Fast (15 minutes)
  • Convenient (same as 2D ultrasound so can be done on first visit)
  • Less expensive (compared to MRI or CT)
  • Safe (ultrasound is a very safe procedure)
  • Uses existing 2D ultrasound equipment
  • Accurate (to gold-standard MRI)
  • Easily verified for each patient (using border alignment [here] and coverage [here] )
  • Easy to learn and use by sonographers and physicians
  • Low capital cost (compared to MRI, CT or 3D echo)
  • Works on virtually everyone (high feasibility)
  • Easy to standardize between operators and hospitals
  • Generates 4-page report with all functional and Qc data as well as 3D images of the heart
  • Exported as a DICOM file, which is compatible with standard PACS archive systems
  • Generates patient history for heart analysis and plots trends
  • Analysis at remote workstation
  • Cloud-computing implementation for remote problem solving and software updates
  • Verified by independent clinical studies to be as accurate as MRI and better than 3D-echo See Journals here
  • Increases MRI productivity by off-loading cardiac MRI patients and freeing up MRI for other cases
  • Shortens waitlist times for cardiac patients requiring routine heart check ups

 

2D to 3D

Better sonography with integrated 2D-3D images

 

The Angelo (VMS™) analytics software provides composite views wherein the 2D plane transects the 3D model showing exactly where the view was taken. It has been the experience of sonographers and cardiologists that this greatly assists them in understanding the anatomy of the heart during sonography and improves their ability to obtain the correct views and excellent coverage of the heart. This is especially helpful when dealing with abnormally shaped right ventricles such as in congenital heart disease or pulmonary hypertension which often require non-standard views.


Coverage

All 2D views shown in 3D reconstruction to verify coverage

 

The Angelo (VMS™) analysis software provides an interactive 3D view of the reconstruction along with the location of all 2D views (yellow lines) obtained from the patient study.  This image can be manipulated to verify the heart has adequate coverage to be certain that all parts of the heart have been captured.  This is a rapid quality control step for the cardiologist to have confidence in the ultrasound study as well as the resultant reconstruction and the functional parameters calculated from the study.


Fit

Fit verified by operator viewing borders on 2D views

 

The Angelo (VMS™) analysis system creates a 3D model of the right ventricle as defined by anatomical landmarks identified in any 2d view by placing “dots” at the correct location. Since Angelo (VMS™) has a built in GPS system, it is able to locate these anatomical landmarks in 3D space and provides this information to the algorithm that then builds the 3D model. The operator can establish how well the model fits by examining the location of the borders, shown in yellow lines, on all the 2D views within the patient study.


If the borders do not look correct, the operator can place additional dots or move the existing dots to properly locate them and then re-run the reconstruction to obtain a new model. Once the operator is satisfied with the fit, the study can be approved and ESV, EDV, EF and CO will automatically be calculated and the patient file updated.


Clinical studies have shown a 0.95 correlation to MRI – several publications confirm the same findings:

  • Echocardiographic assessment of right ventricular volumes after surgical repair of tetralogy of fallot: clinical validation of a new echocardiographic method. Dragulescu A, Grosse-Wortmann L, Fackoury C, Riffle S, Waiss M, Jaeggi E, Yoo SJ, Friedberg MK, Mertens L. J Am Soc Echocardiogr. 2011 Nov;24(11):1191-8. Epub 2011 Sep 15.
  • Accuracy of knowledge-based reconstruction for measurement of right ventricular volume and function in patients with tetralogy of Fallot.Sheehan FH, Kilner PJ, Sahn DJ, Vick GW 3rd, Stout KK, Ge S, Helbing WA, Lewin M, Shurman AJ, Buechel EV, Litt HI, Waiss MP. Am J Cardiol. 2010 Apr 1;105(7):993-9. Epub 2010 Feb 13.
  • Evaluation of midwall systolic function in left ventricular hypertrophy: a comparison of 3-dimensional versus 2-dimensional echocardiographic indices. Jung HO, Sheehan FH, Bolson EL, Waiss MP, Otto CM. J Am Soc Echocardiogr. 2006 Jun;19(6):802-10.
  • Three-dimensional visual guidance improves the accuracy of calculating right ventricular volume with two-dimensional echocardiography.Dorosz JL, Bolson EL, Waiss MS, Sheehan FH. J Am Soc Echocardiogr. 2003 Jun;16(6):675-81.

 

Angelo


The Angelo (VMS™) heart analysis system is named after Michelangelo who taught his students to put dots on a page to get the proportionality correct before drawing an image. Our technology using knowledge-based reconstruction (KBR) works a similar way as we ask medical professionals to identify anatomical landmarks (heart valves, inside wall, outside wall, etc) with dots and a number of 2D ultrasound slices through the heart. We also have a sensor on the ultrasound probe so we know where the 2D slice (plane) is in 3D space and so we can locate the precise anatomical landmark in 3D space. We have found through years of research that a constellation of 25 of these points is all that is required to define the ventricle of the heart and allow an accurate 3D image to be constructed using KBR.


We have built a library of hearts with normal shapes and sizes as well as hearts with the particular abnormality in the heart disease of interest. This library then becomes the catalog of possible shapes and sizes the heart can possibly be. Through a complicated regional statistical process the heart best shape for the 25-point constellation is selected. The resultant heart image is used to calculate heart volumes, ejection fraction and cardiac output. Independent research by leading cardiologists around the world has shown these calculated numbers are just as accurate as MRI, CT or 3D-echo or any other way of measuring the heart.


The big difference is the 2D ultrasound examination takes only 5 minutes and the analysis takes another 10 minutes so you have an accurate heart analysis in 15 minutes compared to at least an hour for the other ways. You also get an answer almost every time, which is not true for MRI, CT or 3D-echo, where either the imaging modality cannot produce a clear image or the patient cannot tolerate the procedure.

 

Angelo’s Advantages

  • Fast (15 minutes) (Workflow Video)
  • Convenient (same as 2D ultrasound so can be done on first visit)
  • Less expensive (compared to MRI or CT)
  • Safe (ultrasound is a very safe procedure)
  • Uses existing 2D ultrasound equipment
  • Accurate (to gold-standard MRI)

George Adams, CEO

  • Dr. Adams is a scientist, a serial entrepreneur and a financier. His previous position was CEO of Amorfix Life Sciences (TSX:AMF) from 2005-2010.
  • He continues as Chairman of Sernova Corp (TSXV:SVA). He was awarded a World Economic Foundation Technology Pioneer for 2007 and TBI Company of the year in 2009.
  • Dr. Adams was the President and CEO of the UT Innovations Foundation from 1999 until 2004.
  • Prior to this, he held research and executive positions with Boston Scientific Inc, Pfizer Inc, Corvita Canada Inc., University of Ottawa and Canadian Red Cross, Blood Transfusion Service.
  • He has been instrumental in founding over 30 companies who have raised $100 million and has been a Director of 10 venture capital funds and 10 start-up companies.
  • Dr. Adams has 124 scientific publications and is a reviewer for major scientific journals, federal granting agencies and Centres of Excellence.

 

Desmond Hirson, President

  • Mr. Hirson is a seasoned executive with over 20 years of experience in commercializing medical devices and managing product development, manufacturing operations, regulatory and quality assurance. He has had multiple successes in start-up ventures and has multiple exits at different companies.
  • Mr. Hirson joined VisualSonics in 2003 as Vice President, Engineering, and led a development team to commercialize novel ultrasound technology from prototype to market success in cardiovascular, cancer and other areas of pre-clinical research that also resulted in ground breaking clinical applications.
  • Prior to this Mr. Hirson developed ultrasound technology for hospital PACS systems, ultrasound image processing and 3D visualization. He continues to show leadership in applying unique technologies to innovative products, and works closely with Sales and Marketing to ensure products meet customer needs.
  • Mr. Hirson obtained a Bachelor of Science Engineering at University of Witwatersrand South Africa and a Masters of Science at the University of Cape Town South Africa and is the inventor on many patents.

 

Ellen Briant, CFO & Corporate Secretary

  • Ms. Briant has twenty years of professional finance experience with an emphasis on private placement and project finance transactions with mid-market and start-up companies.
  • As Vice-President at Spire Sharwood (previously Sharwood & Company) she provided financial advisory services and raised capital for venture and mid-market companies.
  • Ms. Briant was Vice-President & Director in the Corporate Finance Group, at Deloitte & Touche LLP, where she arranged senior and mezzanine debt financing and provided financial strategy and advisory services for various sized clients.
  • Prior to that she was a Corporate Account Relationship Manager with the Corporate Banking Group at Scotiabank and a Senior Accountant with the Financial Services Audit group at Ernst & Young.
  • Ms. Briant received a M.B.A. from the Richard Ivey School of Business at the University of Western Ontario, a B.A. from Queen’s University, and a B.Comm. from the University of Windsor.
  • Ms. Briant earned the Chartered Accountant (C.A.) designation in 1991.

 

Brian Leck, Vice-President,  Direct Worldwide Sales

  • Mr. Leck is a seasoned healthcare professional with extensive industry experience. Prior to joining Ventripoint, Mr. Leck was Global Direct Sales Vice President / General Manager for FUJIFILM Sonosite Inc., an innovator in portable ultrasound for office and hospital care.
  • Mr. Leck ran FUJIFILM Sonosite’s North and South American direct and distributor sales from 2012 to 2014.  He was instrumental in setting up a wholly owned subsidiary in Sao Paulo, Brazil which included sales, marketing, finance, and regulation, as well as a repair facility.
  • Prior to this, Mr. Leck managed Global Direct Sales for FUJIFILM Sonosite in the U. S., Canada, Australia, New Zealand, Korea and Western Europe, as well as a shared services facility in Amsterdam.
  • As Regional Sales Manager for GE Healthcare, Mr. Leck managed the Lunar Bone Densitometry division in states ranging from Texas to North Carolina.
  • Mr. Leck has a Bachelor of Science from the University of Texas.

 

Mehran Mehrtash, Vice-President, Worldwide Distributor Sales

  • Mr. Mehrtash is an experienced international executive in the global healthcare industry. He most recently served as Vice President / General Manager of FUJIFILM Sonosite Inc.’s Global Distribution Division, where he led worldwide indirect operations for point of care ultrasound devices, with oversite of independent distributors in Latin America, Europe, Asia and the Middle East’s emerging markets.  He also had responsibility for FUJIFILM Sonosite subsidiaries in China, India and Japan.
  • Prior to this Mr. Mehrtash ran the FUJIFILM Sonosite Asia, Pacific & Middle East region with full P&L responsibility and annual revenue growth of 20%. Mr. Mehrtash led the establishment of FUJIFILM Sonosite’s regional headquarters in Singapore, and its direct subsidiary in South Korea.
  • At ConvaTec, Inc., Mr. Mehrtash managed all direct and distributor commercial and operational priorities for the Asia Pacific region, including Greater China, South Korea, India and the ASEAN markets.
  • Mr. Mehrtash completed his Bachelor of Arts from Brandeis University in 1987.
  •  

Ventripoint Diagnostics Ltd.

219 Dufferin Street, Suite 8A
Toronto, Ontario, M6K 3J1
​Canada


Phone: +1 (416) 848-4156
Fax: +1 (416) 848-0709
Email: [email protected]

View full VPT profile View Profile
View All

Executive video interviews

VIEW ALL VIDEOS

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.